Dogwood Therapeutics reported third-quarter results alongside progress on its lead pain-treatment candidate, Halneuron. The company has completed a 239-patient Phase 2b trial in chemotherapy-induced neuropathic pain and expects to announce initial results in November.
Dogwood also completed a $5 million private placement with an affiliate of its largest shareholder. The company says its cash and the placement proceeds provide operating runway through the first quarter of 2027.
Clinical and business updates
- The completed Phase 2b trial tested Halneuron in chemotherapy-induced neuropathic pain. Top-line results are expected in November 2026.
- A related 12-week, open-label extension study has enrolled 95 patients who completed the four-week Phase 2b trial. It is intended to assess pain reduction over three months of treatment, with completion expected in early 2027.
- Dogwood closed a $5 million private placement with Sealbond Limited, its largest shareholder and a subsidiary of CK Life Sciences. Proceeds are intended for Halneuron Phase 3 preparatory work, working capital and general corporate purposes. The announcement did not specify the securities issued or their pricing, so the placement’s potential dilution cannot be assessed from the information provided.
- Dogwood said it had $4.9 million in cash on hand and that, combined with the placement, this provides runway through the first quarter of 2027.
- The company’s other development candidate, SP16 IV, is being developed for neuropathy and nerve damage. A planned Phase 1b trial in chemotherapy-induced neuropathy is fully funded by the National Cancer Institute.
Third-quarter financial results
- Revenue was $0.1 million, compared with none a year earlier. It came from Dogwood’s first payment under the PRIDCor license agreement. The company also recorded $0.1 million in related costs payable to holders under a separate agreement.
- Research and development expense fell to $3.3 million from $14.5 million. The main reason was that the prior-year quarter included $12.0 million in acquired research and development costs tied to a licensing agreement. In the latest quarter, spending on the Halneuron trial increased by $0.5 million year over year.
- General and administrative expense rose to $1.6 million from $1.3 million, mainly because of higher salaries and personnel costs.
- Net loss attributable to common stockholders was $4.9 million, or $0.14 per share, compared with $15.7 million, or $8.20 per share, a year earlier. The lower loss coincided with the absence of the large acquired research and development expense recorded in the prior-year quarter.
The near-term clinical focus is the pending Phase 2b result for Halneuron. The announced financing is intended to support preparation for a possible Phase 3 program, while Dogwood’s stated cash runway extends through the first quarter of 2027.